Lung Ultrasonography Scores in Preterm Infants and Respiratory Outcomes at Age 2 Years

Luca Bonadies, MD, PhD; Daniele De Luca, MD, PhD; Maria Auciello, MD; Laura Moschino, MD, PhD; Sabrina Congedi, MD; Daniel Nardo, MD; Eugenio Baraldi, MD

Introduction

Poor respiratory outcomes and frequent respiratory exacerbations are common complications of preterm birth and bronchopulmonary dysplasia (BPD).1 Growing evidence supports the use of lung ultrasonography score (LUS)2 to estimate BPD risk,3 but the association between LUS and later respiratory outcomes is unknown.

Methods

Between September 2019 and November 2022, we enrolled preterm infants (<30 weeks' gestation) to investigate the association between LUS2 within the first 3, 7, and 14 days of life (DOL) and respiratory outcomes (respiratory exacerbations, physician-diagnosed wheezing episodes, and respiratory medication use) at 2 years' corrected age. Clinical data and validated respiratory morbidity score4 were collected. We evaluated LUS as a risk factor for respiratory outcomes, applying area under the receiver operating characteristic curve (AUC) analysis. The Province of Padua Ethics Committee for Clinical Trials approved this cohort study. Parents provided written informed consent. We followed the STROBE reporting guideline.

Two-sided P < .05 indicated statistical significance. Data were analyzed with IBM SPSS Statistics 28.0.1 (IBM). The eMethods in Supplement 1 provides study details.

Results

We enrolled 51 patients (mean [SD] gestational age [GA], 27.3 (1.7) weeks; 20 females [39.2%], 31 males [60.8%]; mean [SD] birth weight: 947 [301] grams), of whom 16 (31%) developed moderate to severe BPD and 8 (16%) mild BPD. After initial discharge, 32 infants (63%) received at least 1 respiratory drug (bronchodilators, corticosteroids, and/or antibiotics), 16 (31%) were hospitalized for respiratory problems, and 3 (3%) needed pediatric intensive care unit (ICU) admission. Mean (SD) respiratory morbidity score at 2 years was 0.51 (0.76).

Compared with infants not receiving drugs or hospitalization, infants needing respiratory drugs had higher median (IQR) LUS at DOL 3 (1 [0-3] vs 6 [3-10]; P = .02), 7 (0 [0-1] vs 5 [2-10]; P < .001), and 14 (1 [0-2] vs 6 [1-11]; P < .001). Among infants needing hospitalization, LUS was higher at DOL 3

<table>
<thead>
<tr>
<th>DOL</th>
<th>Any need for respiratory drugs</th>
<th>Respiratory Morbidity Score</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>p (95% CI)</td>
<td>P value</td>
</tr>
<tr>
<td>3</td>
<td>0.521 (0.252-0.703)</td>
<td>.001</td>
</tr>
<tr>
<td>7</td>
<td>0.762 (0.609-0.861)</td>
<td>.001</td>
</tr>
<tr>
<td>14</td>
<td>0.691 (0.507-0.815)</td>
<td>.001</td>
</tr>
</tbody>
</table>

Abbreviations: Adjusted β, adjusted for gestational age β coefficient; DOL, day of life; p, rho coefficient.

Open Access. This is an open access article distributed under the terms of the CC-BY License.
<table>
<thead>
<tr>
<th>DOL</th>
<th>Any need for respiratory drugs</th>
<th>Any need for respiratory hospitalizations</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(AUC (95% CI))</td>
<td>Sensitivity</td>
</tr>
<tr>
<td>3</td>
<td>0.780 (0.641-0.918)</td>
<td>.002</td>
</tr>
<tr>
<td>7</td>
<td>0.838 (0.722-0.954)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>14</td>
<td>0.792 (0.661-0.923)</td>
<td>.001</td>
</tr>
</tbody>
</table>

Abbreviations: AUC, area under the receiver operating characteristic curve; DOL, day of life; NPV, negative predictive value; PPV, positive predictive value.
Infants needing ICU always had LUS over 8.

At DOL 3, 7, and 14, LUS correlated with number of respiratory exacerbations needing drugs (eg, DOL 7: $p = 0.762$) or hospitalization ($p = 0.663$) and with respiratory morbidity score ($p = 0.714$), and after correction for GA for DOL 7 and 14 (eg, needing drugs: adjusted $\beta = 0.352$ and 0.177) (Table 1). LUS was associated with respiratory outcomes (eg, DOL 7 AUC, 0.838 [needing drugs] and 0.868 [needing hospitalizations]) (Table 2).

**Discussion**

Respiratory outcomes in the first 2 years of life are important clinically among premature infants with BPD. Our findings suggest that infants with later respiratory problems show signs of worse lung aeration measured by LUS in the first 14 DOL.

Significant correlation results after GA correction have been obtained as early as DOL 7, suggesting that a higher LUS at such time points is a risk factor for more frequent respiratory episodes. Different cutoff values have also been identified (higher at later time points), suggesting the presence of an active evolving disease in the lungs toward a higher LUS in infants later affected. Lung ultrasonography performed at DOL 3 may not be associated with long-term outcomes because LUS could be altered by other pathological processes, such as respiratory distress syndrome and patent ductus arteriosus. Good timing to estimate respiratory outcomes seems to be the second week of life, although the ideal DOL remains unknown.

Study limitations are the small sample and inclusion of infants born at 28 to 29 weeks’ gestation with potentially lower risk for respiratory complications. In very preterm neonates, the association of LUS, especially at DOL 7 and 14, with the number of respiratory episodes needing medications and/or hospitalization and with respiratory morbidity score suggests that LUS is a promising tool for estimating respiratory outcomes in the first 2 years of life.
Conflict of Interest Disclosures: Dr De Luca reported receiving personal fees and nonfinancial support from Chiesi; personal fees and nonfinancial support from Getinge; and personal fees from Airway Therapeutics, Vyaire, Ophirex, and Medtronic outside the submitted work. Prof Baraldi reported receiving personal fees from AstraZeneca, Chiesi, and Sanofi for meeting lectures and serving on advisory boards outside the submitted work. No other disclosures were reported.

Meeting Presentation: Preliminary results of this work were presented at the 28th National Congress of the Italian Society of Neonatology; October 27, 2022; Florence, Italy.

Data Sharing Statement: See Supplement 2.

Additional Contributions: Anna Chiara Frigo, PhD, Department of Cardiac, Thoracic and Vascular Sciences, Padova University Hospital, assisted with statistical analysis. Sabrina Salvadori, MD, Department of Woman's and Child's Health, Padova University Hospital, Italy, assisted with data collection. These individuals received no additional compensation, outside of their usual salary, for their contributions.

REFERENCES

SUPPLEMENT 1.
eMethods.
eReferences

SUPPLEMENT 2.
Data Sharing Statement